Apellis Pharmaceuticals (NASDAQ:APLS) Receives Outperform Rating from Robert W. Baird

Robert W. Baird reissued their outperform rating on shares of Apellis Pharmaceuticals (NASDAQ:APLSFree Report) in a research note issued to investors on Tuesday, Benzinga reports. Robert W. Baird currently has a $81.00 price objective on the stock.

APLS has been the subject of several other research reports. Citigroup decreased their target price on Apellis Pharmaceuticals from $70.00 to $67.00 and set a buy rating for the company in a research note on Friday, December 15th. Needham & Company LLC increased their price target on shares of Apellis Pharmaceuticals from $70.00 to $75.00 and gave the stock a buy rating in a research report on Wednesday, January 24th. Wells Fargo & Company downgraded Apellis Pharmaceuticals from an overweight rating to an equal weight rating and decreased their price objective for the company from $67.00 to $54.00 in a report on Thursday, December 14th. The Goldman Sachs Group increased their target price on Apellis Pharmaceuticals from $65.00 to $90.00 and gave the stock a buy rating in a report on Tuesday, January 9th. Finally, Oppenheimer raised their target price on Apellis Pharmaceuticals from $75.00 to $79.00 and gave the stock an outperform rating in a research report on Tuesday, January 30th. Three analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Apellis Pharmaceuticals presently has a consensus rating of Moderate Buy and an average price target of $74.73.

Get Our Latest Analysis on APLS

Apellis Pharmaceuticals Stock Up 0.6 %

Apellis Pharmaceuticals stock opened at $68.56 on Tuesday. The company has a debt-to-equity ratio of 0.40, a current ratio of 4.29 and a quick ratio of 3.76. Apellis Pharmaceuticals has a fifty-two week low of $19.83 and a fifty-two week high of $94.75. The firm has a fifty day moving average price of $63.14 and a two-hundred day moving average price of $49.05. The firm has a market cap of $8.12 billion, a price-to-earnings ratio of -13.06 and a beta of 0.93.

Insider Transactions at Apellis Pharmaceuticals

In related news, General Counsel David O. Watson sold 906 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $64.14, for a total transaction of $58,110.84. Following the transaction, the general counsel now owns 104,171 shares of the company’s stock, valued at approximately $6,681,527.94. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, General Counsel David O. Watson sold 906 shares of the business’s stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $64.14, for a total value of $58,110.84. Following the sale, the general counsel now directly owns 104,171 shares in the company, valued at $6,681,527.94. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Adam J. Townsend sold 3,413 shares of the stock in a transaction dated Monday, January 22nd. The stock was sold at an average price of $65.00, for a total value of $221,845.00. Following the transaction, the insider now owns 94,507 shares of the company’s stock, valued at $6,142,955. The disclosure for this sale can be found here. Insiders have sold 68,826 shares of company stock worth $4,301,015 in the last three months. Insiders own 7.50% of the company’s stock.

Institutional Investors Weigh In On Apellis Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Bank of New York Mellon Corp boosted its position in Apellis Pharmaceuticals by 5.8% during the first quarter. Bank of New York Mellon Corp now owns 315,480 shares of the company’s stock worth $16,029,000 after purchasing an additional 17,287 shares during the period. American Century Companies Inc. acquired a new stake in shares of Apellis Pharmaceuticals during the 1st quarter worth about $820,000. US Bancorp DE boosted its holdings in shares of Apellis Pharmaceuticals by 391.2% during the 1st quarter. US Bancorp DE now owns 1,110 shares of the company’s stock worth $56,000 after buying an additional 884 shares during the period. MetLife Investment Management LLC grew its stake in Apellis Pharmaceuticals by 67.0% in the 1st quarter. MetLife Investment Management LLC now owns 41,293 shares of the company’s stock valued at $2,098,000 after buying an additional 16,567 shares during the last quarter. Finally, Rhumbline Advisers raised its holdings in Apellis Pharmaceuticals by 5.2% in the 1st quarter. Rhumbline Advisers now owns 77,764 shares of the company’s stock valued at $3,951,000 after acquiring an additional 3,835 shares during the period. Institutional investors own 90.43% of the company’s stock.

Apellis Pharmaceuticals Company Profile

(Get Free Report)

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy (GA).

Featured Articles

Analyst Recommendations for Apellis Pharmaceuticals (NASDAQ:APLS)

Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.